CAMBRIDGE, Mass., Feb. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 1,717 shares of its common stock and an aggregate of 858 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity award ...

Blueprint Medicines Corporation (BPMC) is focused on developing transformational precision medicines to address genomically defined cancers and rare diseases.The company’s lead drug, Ayvakit/Ayvakyt (avapritinib), a kinase inhibitor, is approved for three rare cancer indications, both in the United States and the EU. The drug is approved for treating adults with PDGFRA Exon 18 mutant gastrointestinal stromal tumors, adults with advanced systemic mastocytosis and adults with indolent systemic mastocytosis (S ...

Blueprint Medicines (BPMC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual i ...

Third Quarter 2023 Financial Results Not for promotional use Agenda AYVAKIT PERFORMANCE Q3 2023 FINANCIAL PERFORMANCE Kate Haviland Chief Executive Officer Christy Rossi Chief Operating Officer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidate ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Becker Hewes - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Eun Yang - Jefferies Brad Canino - Stifel Reni Benjamin - JMP Securities Salveen ...

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of ...

9 Second Quarter 2023 Financial Results AUGUST 2, 2023 INTRODUCTION AYVAKIT PERFORMANCE KEY PORTFOLIO MILESTONES Q2 2023 FINANCIAL PERFORMANCE Not for promotional use Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candi dates ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Jenna Cohen - VP, IR Kate Haviland - CEO Philina Lee - CCO Fouad Namouni - President, R&D Mike Landsittel - CFO Christy Rossi - COO Becker Hewes - CMO Conference Call Participants Brad Canino - Stifel Dane Leone - Raymond James Reni Benjamin - JMP Securities Eun Yang - Jefferies Marc Frahm - TD Cowen Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Partners Ami Fadia - Ne ...

Table of Contents The Company evaluated the Zai Lab agreement to determine whether it is a collaborative arrangement in the scope of ASC 808. The Company concluded that the Zai Lab agreement is a collaborative agreement under ASC 808 as both parties are active participants in the clinical trials and are exposed to significant risks and rewards of those activities under the Zai Lab agreement. The Company determined that the Zai Lab agreement contained two material components: (i) licenses granted to Zai Lab ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President, Research & Development Christina Rossi - Chief Operating Officer Conference Call Participants Reni Benjamin - JMP Securities Brad Canino - Stifel ...